ClinicalTrials.gg
Active, not recruitingNCT07160816Updated Sep 25, 2026

A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar

An observational study in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Active, not recruiting at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Novo Nordisk A/S · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
245
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S — 2 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Novo Nordisk A/S.

Planned enrollment
67th of 77
245 · median 1,068
Started
2025
with 6 others
Observational
77 of 226
1 open now
Registered
224th of 226
by date

Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 67th largest by planned enrollment of the 77 observational ones that give a count, is one of 7 that started in 2025, is one of 77 observational ones, and was the 224th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 1 diabetes (T1D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population comprises participants who are diagnosed with type 1 diabetes and agree to be treated with insulin icodec after consultation with their physician independently from the decision to participate in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to the protocol).
  • The decision to initiate treatment with commercially available insulin icodec has been made by the participant/legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
  • Male or female, age greater than or equal to (≥) 18 years at the time of signing .
  • Diagnosed with T1D ≥ 1 year before signing informed consent.
  • Treated with multiple daily insulin injections (daily basal insulin analogue and bolus insulin analogue regimen) ≥ 6 months before signing informed consent.
  • Available value less than or equal to (≤) 90 days prior to the 'Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Initiation visit' (V1) if in line with local clinical practice.
  • Treatment naïve to once-weekly insulin prior to the 'Initiation Visit' (V1).

Exclusion criteria

Exclusion Criteria:

  • Previous participation in this study. Participation is defined as having given in this study.
  • Treatment with any drug within 30 days prior to enrolment into the study.
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
245 participants (estimated)
Patient registry
No

Groups and cohorts

  • Insulin icodec

    Participants with T1D will be treated with commercially available insulin icodec according to routine clinical practice at the discretion of the treating physician.

    Drug: Insulin icodec

Interventions

  • Participants with T1D will be treated with commercially available insulin icodec.

    Also known as: Awiqli

06

What researchers measure

Primary outcomes

  1. Change in glycated haemoglobin (HbA1c)

    Measured as percentage (%) point of HbA1c.

    Time frame: Baseline (week 0), week 26

Secondary outcomes

  1. Change in Insulin Treatment Satisfaction Questionnaire (ITSQ) score

    ITSQ measures insulin treatment satisfaction, applicable to a wide range of insulin therapies. The ITSQ consists of 22 items yielding 5 domain scores and a total score. The domains consist of Regimen inconvenience (5 items), Lifestyle flexibility (3 items), Glycemic control (3 items), Hypoglycemic control (5 items), and Satisfaction with the insulin delivery device (6 items). The domain and global ITSQ score both ranges from 0-100.Higher scores indicate a better health state (less negative impact).

    Time frame: Baseline (week 0), end of study (week 22-30)

  2. Change in Adelphi Adherence Questionnaire (ADAQ) score

    The ADAQ measure consists of 11 items scored on a scale of 0 to 4. The mean of the individual items represents the total ADAQ score. At least 8 of the 11 items must be answered to calculate the ADAQ score. The lower the score corresponds to the greater adherence.

    Time frame: Baseline (week 0), end of study (week 22-30)

  3. Number of self-reported overall severe hypoglycaemia

    Measured as number of episodes.

    Time frame: From baseline (week 0) to end of study (week 22-30)

  4. Clinical success as perceived by the physician

    Measured as count of participant per response option.

    Time frame: From baseline (week 0) to end of study (week 22-30)

07

Study locations

37 sites
  • Hausärztliche und Diabetologische Praxis Pirna
    Pirna, LÄK Sachsen 01796, Germany
  • Zuckerpraxis Dr. Ewald Jammers
    Bramsche, 49565, Germany
  • Studiengesellschaft Dres. Könemann/Steinmann GbR
    Bünde, 32257, Germany
  • Diabeteszentrum-Do Dres. K U. Ch. Busch GbR
    Dortmund, 44137, Germany
  • Diabeteszentrum Duisburg-Mitte
    Duisburg, 47051, Germany
  • MVZ im Altstadt-Carree Fulda GmbH - Zentrum für klinische Studien
    Fulda, 36037, Germany
  • Gemeinschaftspraxis Dr. Martin Grüneberg
    Herne, 64649, Germany
  • Mesut Durmaz, Hof
    Hof, 95030, Germany
  • Dr. Carola Lüke
    Jerichow, 39319, Germany
  • Diabetespraxis Kiel
    Kiel, 24114, Germany
  • Praxis Am Oberen Tor - Dr. Simon-Wagner
    Lichtenfels, 96215, Germany
  • Diabetologie Dr. Eidenmüller
    Marburg, 35037, Germany
  • Dr. Bernhard Landers
    Mayen, 56727, Germany
  • Diabeteszentrum Bogenhausen
    München, 81927, Germany
  • Medicover Neu-Ulm MVZ
    Neu-Ulm, 89231, Germany
  • Diabetespraxis Oranienburg
    Oranienburg, 16515, Germany
  • Diabetesschwerpunktpraxis Dr. Martina Lange
    Rheinbach, 53359, Germany
  • Med.Versorgungszentrum Riesa-Dr. Bieler
    Riesa, 01587, Germany
  • Dr. med. Carsten Schürfeld, GZ-Vauban
    Saarlouis, 66740, Germany
  • Diabetespraxis Schorndorf Dr. Hensel
    Schorndorf, 73614, Germany
  • Praxis Dr. Zimmermann
    Sonsbeck, 47665, Germany
  • Endokrinologikum Ulm
    Ulm, 89073, Germany
  • Diabetespraxis Viersen
    Viersen, 41747, Germany
  • ASST FBF Sacco - Ospedale Fatebenefratelli e Oftalmico - Oculistica - Istituto Oftalmico
    Milan, Lombardy 20121, Italy
  • ASST Fatebenefratelli Sacco - Ospedale Macedonio Melloni
    Milan, Lombardy 20129, Italy
  • Ospedale San Raffaele S.r.l. - Unità Clinica Endocrinologia
    Milan, Lombardy 20132, Italy
  • ASST FBF Sacco - Ospedale Luigi Sacco
    Milan, Lombardy 20157, Italy
  • Azienda Sanitaria Locale Città di Torino - Ambulatorio Endocrinologia e Malattie Metaboliche
    Turin, Piedmont 10122, Italy
  • AUSL Toscana Nord Ovest - Ospedali Riuniti di Livorno - Diabetologia e Malattie del Metabolismo
    Livorno, Tuscany 57124, Italy
  • AUSL Toscana Nord Ovest - Cittadella della Salute Campo di Marte - Diabetologia Lucca e Valle del Serchio
    Lucca, Tuscany 55100, Italy
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Azienda Ospedaliero-Universitaria Renato Dulbecco
    Catanzaro, 88100, Italy
  • A.O.U. Università Studi della Campania "Luigi Vanvitelli"
    Naples, 80138, Italy
  • Azienda Ospedaliera di Perugia;Ospedale S. Maria della Misericordia
    Perugia, 06129, Italy
  • DIABETOLOGIA Ravenna AUSL della Romagna
    Ravenna, 48121, Italy
  • Universita Degli Studi Di Roma La Sapienza - Policlinico Umberto I Medicina Sperimentale
    Roma, 00161, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Dipartimento di scienze Mediche e Chirurgiche
    Rome, 00168, Italy
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 16 months is below that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 8, 2025
StartActual
Aug 28, 2025
Primary completionEst.
Jan 20, 2027
CompletionEst.
Jan 20, 2027
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07160816
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Aug 28, 2025
Primary completion
Jan 20, 2027 (estimated)
Completion
Jan 20, 2027 (estimated)
Last update
Sep 25, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion